ERBB2 and breast cancer: Pierini et al., established a relevant immunocompetent syngeneic mouse model (36) to study the antitumor capacity of bone marrow-derived CAR-Ms targeting HER2 antigens on murine CT26 colorectal and human AU-565 breast cancer cell lines.